Figure 2

A and B, Kaplan-Meier survival curves of tumor-bearing mice following treatment with scFvMTBHsp70, control proteins or normal saline. A, In a syngeneic mouse model of papillary ovarian cancer in immune-competent FVB/NJ mice, scFvMTBHsp70 prolonged ascites-free survival time compared with saline (n = 10 per group, representative of two independent experiments; median survival (Med. sur.) = 47 days vs. 37.5 days), or the mixture of MTBHsp70 plus P4 scFv (Med. sur. = 39 days). scFvMTBHsp70 also prolonged overall survival time in the mice compared with saline (Med. sur. = 51.5 days vs. 43 days), or the mixture of MTBHsp70 plus P4 scFv (Med. sur. = 43 days). B, In a syngeneic mouse model of mesothelioma in immune-competent C57BL/6 mice, the fusion protein prolonged ascites-free survival time compared with saline-treated mice (n = 20 per group, pooled from two independent experiments; Med. sur. = 28 days vs. 26 days), or the mixture of MTBHsp70 plus P4 scFv (Med. sur. = 27 days). The fusion protein also prolonged overall survival time compared with saline (Med. sur. = 36 days vs. 31 days). P values were determined using the log-rank test. *,p < 0.05; **,p < 0.01; ***,p < 0.001.